Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
The CRISPR pioneer Feng Zhang is launching yet another ambitious gene-editing startup, backed by approximately $200 million from some of biotech's biggest investors. The Cambridge, Massachusetts ...
Hosted on MSN10mon
A decade after sparking the Seaport’s boom, Vertex is considering leaving Fan PierWith the lease on its two-building ... Boston area, according to Nichols. The company is best known for its drugs to treat the rare disease cystic fibrosis, but it also co-developed, with CRISPR ...
ZUG, Switzerland and BOSTON, Jan. 13 ... Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Building on the success of CASGEVY’s launch, we continue to broaden our portfolio ...
“Building on the success of CASGEVY&CloseCurlyQuote ... with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, ...
“Building on the success of CASGEVY ... with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback